FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OIVID APPROVAL										
	OMB Number:	3235-0287									
l	Estimated average burde	en									

hours per response:

0.5

	Check this box if no longer subject to
ĺ	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					- 01	1 3000	.1011 30(11) (or tile ii	iivesiiileii	COII	ipariy Act	01 1340								
Name and Address of Reporting Person* Tenenbaum Fabian				2. Issuer Name and Ticker or Trading Symbol Bellerophon Therapeutics, Inc. [BLPH]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
													_ X	Officer (give title		Other (s	·		
(Last) (First) (Middle) 184 LIBERTY CORNER ROAD					3. Date of Earliest Transaction (Month/Day/Year) 11/29/2016									Chief Executive Officer						
SUITE 3	02								0									(0)		
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Inc Line)	6. Individual or Joint/Group Filing (Check Applicable Line)					
WARRE	N N	J	07059											X		,		rting Persor One Repor		
(6:1)											Person	eu by Mor	e man	Опе керог	uriy					
(City)	(S	tate)	(Zip)																	
		Та	ble I - Non	-Deriv	ativ	re Se	curities	s Acq	uired,	Disp	osed c	f, or E	ene	ficially	Owned					
D			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. r) 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		A) or 3, 4 and 5	Securities Beneficia Owned Fo	Beneficially Dwned Following		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A	or	Price	Reported Transacti (Instr. 3 a	on(s)			(Instr. 4)		
Common Stock				11/29	9/2016				P		142,857 A		A	(1)	142,857			D		
			Table II - D				urities ls, warr								Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code (Instr.			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exe Expiration (Month/Da	Date	of Securities		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Co	ode	v		Oate Exercisabl		xpiration ate	Title	or Nu	nount ımber Shares		Transaction(s) (Instr. 4)		'			
Common Stock Warrants (right to	\$0.8	11/29/2016		1	P		142,857		11/29/2010	5 1:	1/29/2021	Commo Stock	n 14	42,857	(1) 142,857		57	D		

Explanation of Responses:

1. The reported securities are included within 142,857 Class A Units purchased by the reporting person for \$0.70 per Class A Unit. Each Class A Unit consists of one share of common stock and one warrant to purchase one share of common stock.

Remarks:

buy)

/s/ Fabian Tenenbaum

12/01/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.